Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

We are optimistic about the promising results reported by Michael S Lee and colleagues1 regarding the use of atezolizumab with or without bevacizumab (GO30140 study) for patients with unresectable hepatocellular carcinoma.1 The investigators found that atezolizumab plus bevacizumab showed promising efficacy (objective response rate 36% [95% CI 26-46]) in group A (single arm); the combination also resulted in longer progression-free survival (5·6 months [95% CI 3·6–7·4] vs 3·4 months [1·9–5·2]; hazard ratio 0·55 [80% CI 0·40–0·74], p=0·011) in group F (randomised group) than atezolizumab alone in patients with unresectable hepatocellular carcinoma.